200
Participants
Start Date
February 23, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
SNV1521
SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Trastuzumab Deruxtecan
Trastuzumab Deruxtecan is given as an infusion based upon prescribing information.
RECRUITING
Scientia Clinical Research, Randwick
RECRUITING
The Alfred Hospital, Melbourne
RECRUITING
Princess Alexandra Hospital, Woolloongabba
RECRUITING
Linear Clinical Research, Crawley
RECRUITING
Thomas Jefferson University, Philadelphia
RECRUITING
Sarah Cannon Research Institute, Nashville
RECRUITING
The University of Texas M.D. Anderson Cancer Center, Houston
RECRUITING
START Center for Cancer Care, West Valley City
RECRUITING
Yale University, New Haven
Synnovation Therapeutics, Inc.
INDUSTRY